U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 5

1.
Figure 4

Figure 4. From: Osteoporosis and aromatase inhibitors: experience and future prospects.

Subjects who recommended the bone mineral densitometry.

Daniela Bosco. Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.
2.
Figure 2

Figure 2. From: Osteoporosis and aromatase inhibitors: experience and future prospects.

Numbers of subjects who performed the bone mineral densitometry depending on when aromatase inhibitors were initiated.

Daniela Bosco. Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.
3.
Figure 5

Figure 5. From: Osteoporosis and aromatase inhibitors: experience and future prospects.

Knowledge of the negative effect on bone health by the aromatase inhibitors.

Daniela Bosco. Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.
4.
Figure 3

Figure 3. From: Osteoporosis and aromatase inhibitors: experience and future prospects.

Results of bone mineral densitometry in the subgroups of patients divided by the timing of the performance of the radiological exam.

Daniela Bosco. Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.
5.
Figure 1

Figure 1. From: Osteoporosis and aromatase inhibitors: experience and future prospects.

Questionnaire relating to booking procedures of the bone mineral densitometry and about the women’s knowledge of osteoporosis related to the use of aromatase inhibitors.

Daniela Bosco. Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center